Nanoform Finland Plc has recently entered into a strategic partnership with CBC Co. The partnership aims to leverage CBC’s extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform’s nanomedicine engineering technologies.
As Christian Jones, Chief Commercial Officer at Nanoform, emphasizes, this partnership is a significant milestone in Nanoform’s mission to deliver meaningful innovation to patients more rapidly. He is excited about the potential of bringing innovative nanotechnology to improve medicines globally.
Shinya Miyairi, Managing Executive Officer at CBC, believes that Nanoform’s technologies align well with the Japanese market’s need for medicines with higher bioavailability and fewer, smaller doses for success. Nanoform’s technology has demonstrated efficacy in various in vitro and in vivo studies across different routes of administration and molecule types.
The partnership between Nanoform and CBC has already begun, with planned joint activities to showcase their collaboration. This includes Nanoform’s representation by CBC at the upcoming CPHI Japan event scheduled to take place at Tokyo Big Sight, Tokyo from April 17-19, 2024. The partnership is set to bring innovative nanomedicine solutions to the forefront of the pharmaceutical industry in Japan.
